Invion Limited (ASX:IVX) has completed the Phase II clinical trial of its treatment for the autoimmune disease Lupus with data showing positive effects after one month of dosing.
A review of safety and biochemical markers of effect in 28 subjects across four cohorts showed the study had met its objectives.
This supported continued development of INV103 (ALA-CPN10) in longer and larger trials in patients with autoimmune diseases.
The company is focused on finding partners for the drug.
Invion had $2.29 million in cash as at 30th June 2015.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.004(4.17%) |
Mkt cap ! $8.541M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 10.0¢ | 9.6¢ | $6.613K | 66.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75887 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 294638 | 3 |
View Market Depth
| Last trade - 15.14pm 30/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |